Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Small extracellular vesicles from menstrual blood-derived mesenchymal stem cells (MenSCs) as a novel therapeutic impetus in regenerative medicine

Fig. 2

The strategy for developing clinical applications of MenSC-derived small EVs. Tissue donors should be selected and examined for MenSC-derived small EVs production. Donors can be autologous or allogeneic obtained from menstrual blood. MenSCs modification by bioengineering [CRISPR/Cas9, small molecules, synthetic mRNA, virus transfection (lentivirus/adenovirus), recombinant proteins] may be considered to improve therapeutic efficacy of MenSC-derived small EVs. Therapeutic effects of engineered MenSC may be further improved by encapsulating miRNA or siRNA in them. The application of MenSC-derived small EVs first evaluated the safety and effectiveness through an animal disease model. Then, MenSC-derived small EVs were employed to treat a variety of diseases in the clinic

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512